Dan C Chambers

Prof. Dr. Dan C Chambers


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2026 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DCDan C Chambers
Dan C Chambers
GWGlen Westall
Glen Westall
DDDavid Darley
David Darley
MMMichael Musk
Michael Musk
AGAllan R. Glanville
Allan R. Glanville
PHPeter M.A. Hopkins
Peter M.A. Hopkins

9 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
Simon H ApteSimon H Apte
Simon H Apte
VLViviana Lutzky
Viviana Lutzky
PGPenny Groves
Penny Groves
DCDan C Chambers
Dan C Chambers
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive parenchymal remodelling, driven by epithelial dysfunction, fibroblast activation, and altered immune regulation within the distal lung. Alveolar macrophages (AMs) reside in a surfactant-rich environment and are specialised for continuous lipid handling, yet the significance of this metabolic role for macrophage heterogeneity and fibrotic progression has remained incompletely integrated across studies. In this review, we synthesise evidence from human lung tissue, experimental models, lipidomic analyses, and clinical investigations to place macrophage populations described in IPF—including FABP4-high homeostatic cells and SPP1-associated disease-enriched states—within a unified lipid-metabolic context. We show that macrophage heterogeneity in IPF can be understood as a variation within a core lipid-handling programme rather than the emergence of distinct macrophage lineages. Profibrotic macrophage states are characterised by altered lipid processing and signalling, including dysregulated sterol handling, lysophospholipid pathways, and eicosanoid balance, which impair surfactant turnover and contribute to fibroblast activation. Importantly, experimental and clinical data indicate that macrophage lipid-metabolic programmes remain modifiable, although definitive disease-modifying efficacy in IPF has yet to be established. Framing macrophage states within a lipid-metabolic framework provides a coherent basis for interpreting heterogeneous datasets and supports the rationale for therapeutic strategies aimed at stabilising or restoring macrophage lipid handling in fibrotic lung disease.

24 September 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
KKKiara Knuckey
Kiara Knuckey
STSjane Timmins
Sjane Timmins
APAmy Pham
Amy Pham
MTMaxine Tan
Maxine Tan
PGPenny Groves
Penny Groves
Simon H ApteSimon H Apte
Simon H Apte
Repeated molecular sampling of the distal airways is constrained by the invasive nature of bronchoalveolar lavage (BAL), limiting its use in healthy control populations, longitudinal studies, clinical trials and occupational screening. Particles in exhaled air (PExA) sampling offers a non-invasive approach to distal-airway sampling, although whether it captures the same proteins and relative protein abundance as BAL has not been established. We performed the first proof-of-principle high-dimensional proteomic comparison of matched BAL and PExA samples collected from three individuals with silicosis using the SomaScan 11K platform. Within individuals, PExA and BAL shared a substantial subset of detectable proteins and showed similar cross-protein signal patterns, with Pearson correlation coefficients ranging from 0.48 to 0.71. Analytes recurrently detected across all three PExA samples were strongly enriched among those consistently detected in BAL and included pulmonary surfactant proteins and mediators associated with epithelial injury, alveolar macrophage function, inflammation and fibrosis. The PExA findings also showed substantial overlap with an independent published PExA-only proteomic dataset. These proof-of-principle findings show that non-invasive PExA sampling can capture a biologically meaningful subset of the matched BAL proteome. PExA may therefore offer a practical approach for repeated molecular profiling of the distal airways and warrants further evaluation for respiratory biomarker discovery and disease monitoring.

26 June 2026 in Cells
Verified
Journal Article
Open access
PDF file
VLViviana Lutzky
Viviana Lutzky
SRSubash Kumar Rai
Subash Kumar Rai
MTMaxine Tan
Maxine Tan
PGPenny Groves
Penny Groves
KKKiara Knuckey
Kiara Knuckey
DCDan C Chambers
Dan C Chambers
Telomere length (TL) measurement is increasingly used in the evaluation of pulmonary fibrosis and suspected telomere biology disorders, with flow cytometry–fluorescence in situ hybridisation (Flow-FISH) representing the current clinical reference standard. However, Flow-FISH provides a population-averaged relative TL, has a high analytical variability and is largely restricted to PBMC-based measurements. We evaluated a long-read sequencing–based assay, Telo-Seq, for clinical TL assessment in an Australian cohort. In this observational study, TL was measured by both Flow-FISH and Telo-Seq in PBMC from 156 healthy controls and a small cohort of 24 patients undergoing clinical evaluation for interstitial lung disease, using the same blood processing and assay workflows. In an exploratory subset of samples, TL was also assessed in whole lung lavage fluid and explanted lung tissue. In the assessment of PBMC, Telo-Seq correlated with Flow-FISH (R2 ≈ 0.77) and showed lower inter-assay variability (CV ~1.4% vs. ~4.6%). Classification relative to assay-specific age-adjusted 10th-percentile thresholds was largely concordant between Flow-FISH and Telo-Seq, although discordant cases occurred in both directions near clinically relevant thresholds. Long-read sequencing provides a reproducible approach to TL assessment and supports further evaluation in disease-relevant tissues.